SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
CODX reported Third Quarter 2026 results. The price and volatility reaction is pending.
CODXearnings

Earnings reactions, page 4

Co-Diagnostics, Inc. (CODX) Q3 FY2026 earnings

November 10, 2026 · SharpeIQ Research Desk

Reported results

  • Revenue was $0.3 million for Q3 2026, compared to $0.1 million in the third quarter of 2025.
  • Operating expenses were $6.2 million, compared to $7.1 million in the third quarter of 2025.
  • Operating loss was $6.3 million, compared to $7.0 million in the third quarter of 2025.
  • GAAP net loss was $6.3 million, or $1.01 per basic and diluted share, compared to a net loss of $5.9 million, or $4.66 per basic and diluted share, in Q3 2025.
  • Non-GAAP Adjusted EBITDA loss was $5.9 million, compared to a loss of $6.3 million in the third quarter of 2025.
  • Cash and cash equivalents totaled $0.7 million as of September 30, 2026.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-10 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →